Glaukos Announces Third Quarter 2023 Financial Results : vim

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key h...

Related Keywords

Thomas Burns , Chris Lewis , Investor Relations Corporate Affairs , International Glaucoma , Exchange Commission , Glaukos Corporation , Avedro Inc , Corneal Health , Investor Relations , Quarterly Summary , Micro Invasive Glaucoma Surgery , Quarterly Report , Investor Section , Regarding Use , Generally Accepted Accounting Principles , Corporate Affairs ,